Ferroptosis and cell death mechanisms in Parkinson's disease

Neurochemistry International

Volumn 104, Issue , 2017, Pages 34-48

  Guiney, Stephanie J ^a   Adlard, Paul A ^a   Bush, Ashley I ^a   Finkelstein, David I ^a   Ayton, Scott ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alpha synuclein; Cell death; Ferroptosis; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CASPASE; GLUTATHIONE; IRON;

ANOIKIS; APOPTOSIS; AUTOPHAGY; CELL DEATH; DISEASE COURSE; FERROPTOSIS; HUMAN; LIPID PEROXIDATION; MITOSIS; MOLECULAR PATHOLOGY; NECROPTOSIS; NONHUMAN; PARKINSON DISEASE; PARTHANATOS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PYROPTOSIS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DOPAMINERGIC NERVE CELL; METABOLISM; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; CELL DEATH; DOPAMINERGIC NEURONS; GLUTATHIONE; PARKINSON DISEASE;

EID: 85009738319     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2017.01.004     Document Type: Review

References (241)

1. Ahlskog, J.E., Muenter, M.D., Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. Official J. Mov. Disord. Soc. 16 (2001), 448–458.
2. Almeida, R.D., Manadas, B.J., Melo, C.V., Gomes, J.R., Mendes, C.S., Graos, M.M., Carvalho, R.F., Carvalho, A.P., Duarte, C.B., Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. 12 (2005), 1329–1343.
3. Ame, J.C., Spenlehauer, C., de Murcia, G., The PARP superfamily. BioEssays News Rev. Mol. Cell. Dev. Biol. 26 (2004), 882–893.
4. Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M.T., Michel, P.P., Marquez, J., Mouatt-Prigent, A., Ruberg, M., Hirsch, E.C., Agid, Y., Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12 (1997), 25–31.
5. Aoudjit, F., Vuori, K., Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J. Cell Biol. 152 (2001), 633–643.
6. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J., Aasly, J.O., Rajput, A., Rajput, A.H., Jon Stoessl, A., Farrer, M.J., Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. Official J. Mov. Disord. Soc. 28 (2013), 811–813.
7. Ayton, S., Parkinson's Disease Iron Deposition Caused by Nitric Oxide-induced Loss of APP. 2015.
8. Ayton, S., Faux, N.G., Bush, A.I., Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat. Commun., 6, 2015, 6760.
9. Ayton, S., Lei, P., Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed. Res. Int., 2014, 2014, 581256.
10. Ayton, S., Lei, P., Adlard, P.A., Volitakis, I., Cherny, R.A., Bush, A.I., Finkelstein, D.I., Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease. Mol. Neurodegener., 9, 2014, 27.
11. Ayton, S., Lei, P., Duce, J.A., Wong, B.X., Sedjahtera, A., Adlard, P.A., Bush, A.I., Finkelstein, D.I., Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann. Neurol. 73 (2013), 554–559.
12. Ayton, S., Lei, P., Hare, D.J., Duce, J.A., George, J.L., Adlard, P.A., McLean, C., Rogers, J.T., Cherny, R.A., Finkelstein, D.I., Bush, A.I., Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J. Neurosci. Official J. Soc. Neurosci. 35 (2015), 3591–3597.
13. Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q., Iwatsubo, T., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152 (1998), 879–884.
14. Banati, R.B., Daniel, S.E., Blunt, S.B., Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. Official J. Mov. Disord. Soc. 13 (1998), 221–227.
15. Bannai, S., Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J. Biol. Chem. 261 (1986), 2256–2263.
16. Bartzokis, G., Cummings, J., Perlman, S., Hance, D.B., Mintz, J., Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56 (1999), 569–574.
17. Beal, M.F., Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44 (1998), S110–S114.
18. Beraud, D., Twomey, M., Bloom, B., Mittereder, A., Ton, V., Neitzke, K., Chasovskikh, S., Mhyre, T.R., Maguire-Zeiss, K.A., Alpha-synuclein alters toll-like receptor expression. Front. Neurosci., 5, 2011, 80.
19. Bilinski, T., Krawiec, Z., Liczmanski, A., Litwinska, J., Is hydroxyl radical generated by the Fenton reaction in vivo?. Biochem. Biophys. Res. Commun. 130 (1985), 533–539.
20. Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H., Riederer, P., Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202 (1995), 17–20.
21. Blum, D., Wu, Y., Nissou, M.F., Arnaud, S., Alim Louis, B., Verna, J.M., p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res. 751 (1997), 139–142.
22. Boland, B., Kumar, A., Lee, S., Platt, F.M., Wegiel, J., Yu, W.H., Nixon, R.A., Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J. Neurosci. Official J. Soc. Neurosci. 28 (2008), 6926–6937.
23. Borie, C., Gasparini, F., Verpillat, P., Bonnet, A.M., Agid, Y., Hetet, G., Brice, A., Durr, A., Grandchamp, B., g. French Parkinson's disease genetic study. Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 249 (2002), 801–804.
24. Bove, J., Martinez-Vicente, M., Dehay, B., Perier, C., Recasens, A., Bombrun, A., Antonsson, B., Vila, M., BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy 10 (2014), 889–900.
25. Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003), 197–211.
26. Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., Del Tredici, K., Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318 (2004), 121–134.
27. Brauer, R., Bhaskaran, K., Chaturvedi, N., Dexter, D.T., Smeeth, L., Douglas, I., Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study. PLoS Med., 12, 2015, e1001854.
28. Brennan, M.A., Cookson, B.T., Salmonella induces macrophage death by caspase-1-dependent necrosis. Mol. Microbiol. 38 (2000), 31–40.
29. Brunner, T., Mogil, R.J., LaFace, D., Yoo, N.J., Mahboubi, A., Echeverri, F., Martin, S.J., Force, W.R., Lynch, D.H., Ware, C.F., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373 (1995), 441–444.
30. Buttner, S., Habernig, L., Broeskamp, F., Ruli, D., Vogtle, F.N., Vlachos, M., Macchi, F., Kuttner, V., Carmona-Gutierrez, D., Eisenberg, T., Ring, J., Markaki, M., Taskin, A.A., Benke, S., Ruckenstuhl, C., Braun, R., Van den Haute, C., Bammens, T., van der Perren, A., Frohlich, K.U., Winderickx, J., Kroemer, G., Baekelandt, V., Tavernarakis, N., Kovacs, G.G., Dengjel, J., Meisinger, C., Sigrist, S.J., Madeo, F., Endonuclease G mediates alpha-synuclein cytotoxicity during Parkinson's disease. EMBO J. 32 (2013), 3041–3054.
31. Casarejos, M.J., Solano, R.M., Gomez, A., Perucho, J., de Yebenes, J.G., Mena, M.A., The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells. Neurochem. Int. 58 (2011), 512–520.
32. Cassarino, D.S., Fall, C.P., Swerdlow, R.H., Smith, T.S., Halvorsen, E.M., Miller, S.W., Parks, J.P., Parker, W.D. Jr., Bennett, J.P. Jr., Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362 (1997), 77–86.
33. Chinta, S.J., Mallajosyula, J.K., Rane, A., Andersen, J.K., Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 486 (2010), 235–239.
34. Chittenden, T., Flemington, C., Houghton, A.B., Ebb, R.G., Gallo, G.J., Elangovan, B., Chinnadurai, G., Lutz, R.J., A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 14 (1995), 5589–5596.
35. Chu, Y., Dodiya, H., Aebischer, P., Olanow, C.W., Kordower, J.H., Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35 (2009), 385–398.
36. Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., de Bernard, M., Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One, 8, 2013, e55375.
37. Corti, O., Hampe, C., Koutnikova, H., Darios, F., Jacquier, S., Prigent, A., Robinson, J.C., Pradier, L., Ruberg, M., Mirande, M., Hirsch, E., Rooney, T., Fournier, A., Brice, A., The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet. 12 (2003), 1427–1437.
38. Cosi, C., Colpaert, F., Koek, W., Degryse, A., Marien, M., Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice. Brain Res. 729 (1996), 264–269.
39. Cosi, C., Marien, M., Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. Ann. N. Y. Acad. Sci. 890 (1999), 227–239.
40. Costello, D.J., Walsh, S.L., Harrington, H.J., Walsh, C.H., Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series. J. Neurol. Neurosurg. Psychiatry 75 (2004), 631–633.
41. Crabtree, D., Dodson, M., Ouyang, X., Boyer-Guittaut, M., Liang, Q., Ballestas, M.E., Fineberg, N., Zhang, J., Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells. J. Neurochem. 128 (2014), 950–961.
42. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., Sulzer, D., Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 (2004), 1292–1295.
43. D'Herde, K., Krysko, D.V., Ferroptosis: oxidized PEs trigger death. Nat. Chem. Biol. 13 (2017), 4–5.
44. Dai, M.C., Zhong, Z.H., Sun, Y.H., Sun, Q.F., Wang, Y.T., Yang, G.Y., Bian, L.G., Curcumin protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosis. Neurosci. Lett. 536 (2013), 41–46.
45. Damier, P., Hirsch, E.C., Agid, Y., Graybiel, A.M., The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain J. Neurol. 122:Pt 8 (1999), 1437–1448.
46. David, K.K., Andrabi, S.A., Dawson, T.M., Dawson, V.L., Parthanatos, a messenger of death. Front. Biosci. 14 (2009), 1116–1128.
47. Davies, P., Moualla, D., Brown, D.R., Alpha-synuclein is a cellular ferrireductase. PLos One, 6, 2011, e15814.
48. Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G.D., Mitchison, T.J., Moskowitz, M.A., Yuan, J., Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1 (2005), 112–119.
49. Dehay, B., Bove, J., Rodriguez-Muela, N., Perier, C., Recasens, A., Boya, P., Vila, M., Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. Official J. Soc. Neurosci. 30 (2010), 12535–12544.
50. Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M.H., Doudnikoff, E., Vital, A., Vila, M., Klein, C., Bezard, E., Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 9611–9616.
51. Desplats, P., Lee, H.J., Bae, E.J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., Lee, S.J., Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 13010–13015.
52. Devos, D., Moreau, C., Devedjian, J.C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garcon, G., Rouaix, N., Duhamel, A., Jissendi, P., Dujardin, K., Auger, F., Ravasi, L., Hopes, L., Grolez, G., Firdaus, W., Sablonniere, B., Strubi-Vuillaume, I., Zahr, N., Destee, A., Corvol, J.C., Poltl, D., Leist, M., Rose, C., Defebvre, L., Marchetti, P., Cabantchik, Z.I., Bordet, R., Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. 21 (2014), 195–210.
53. Devos, D., Moreau, C., Kluza, J., Laloux, C., Petrault, M., Devedjian, J.-C., Ryckewaert, G., Garcon, G., Rouaix, N., Jissendi, P., Disease modifying strategy based upon iron chelation in Parkinson's disease: a translational study (P02. 240). Neurology, 78(P02), 2012, 240.
54. Dexter, D., Carter, C., Agid, F., Agid, Y., Lees, A.J., Jenner, P., Marsden, C.D., Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2 (1986), 639–640.
55. Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F.R., Daniel, S.E., Lees, A.J., Jenner, P., Marsden, C.D., Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain J. Neurol. 114:Pt 4 (1991), 1953–1975.
56. Dexter, D.T., Carter, C.J., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., Marsden, C.D., Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52 (1989), 381–389.
57. Dexter, D.T., Wells, F.R., Lees, A.J., Agid, F., Agid, Y., Jenner, P., Marsden, C.D., Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52 (1989), 1830–1836.
58. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., Morrison, B. 3rd, Stockwell, B.R., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
59. Dixon, S.J., Winter, G.E., Musavi, L.S., Lee, E.D., Snijder, B., Rebsamen, M., Superti-Furga, G., Stockwell, B.R., Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem. Biol. 10 (2015), 1604–1609.
60. Do Van, B., Gouel, F., Jonneaux, A., Timmerman, K., Gele, P., Petrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., Devos, D., Devedjian, J.C., Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. Neurobiol. Dis. 94 (2016), 169–178.
61. Doll, S., Proneth, B., Tyurina, Y.Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., Prokisch, H., Trumbach, D., Mao, G., Qu, F., Bayir, H., Fullekrug, J., Scheel, C.H., Wurst, W., Schick, J.A., Kagan, V.E., Angeli, J.P., Conrad, M., ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13 (2017), 91–98.
62. Donovan, A., Lima, C.A., Pinkus, J.L., Pinkus, G.S., Zon, L.I., Robine, S., Andrews, N.C., The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 1 (2005), 191–200.
63. Duce, J.A., Tsatsanis, A., Cater, M.A., James, S.A., Robb, E., Wikhe, K., Leong, S.L., Perez, K., Johanssen, T., Greenough, M.A., Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142 (2010), 857–867.
64. Edwards-Lee, T., Ringman, J.M., Chung, J., Werner, J., Morgan, A., St George Hyslop, P., Thompson, P., Dutton, R., Mlikotic, A., Rogaeva, E., Hardy, J., An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology 64 (2005), 377–379.
65. Edwards, T.L., Scott, W.K., Almonte, C., Burt, A., Powell, E.H., Beecham, G.W., Wang, L., Zuchner, S., Konidari, I., Wang, G., Singer, C., Nahab, F., Scott, B., Stajich, J.M., Pericak-Vance, M., Haines, J., Vance, J.M., Martin, E.R., Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74 (2010), 97–109.
66. Edwards, Y.J., Beecham, G.W., Scott, W.K., Khuri, S., Bademci, G., Tekin, D., Martin, E.R., Jiang, Z., Mash, D.C., ffrench-Mullen, J., Pericak-Vance, M.A., Tsinoremas, N., Vance, J.M., Identifying consensus disease pathways in Parkinson's disease using an integrative systems biology approach. PLoS One, 6, 2011, e16917.
67. Fearnley, J.M., Lees, A.J., Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain J. Neurol. 114:Pt 5 (1991), 2283–2301.
68. Febbraro, F., Giorgi, M., Caldarola, S., Loreni, F., Romero-Ramos, M., alpha-Synuclein expression is modulated at the translational level by iron. Neuroreport 23 (2012), 576–580.
69. Ferrari, C.C., Pott Godoy, M.C., Tarelli, R., Chertoff, M., Depino, A.M., Pitossi, F.J., Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol. Dis. 24 (2006), 183–193.
70. Fink, S.L., Bergsbaken, T., Cookson, B.T., Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 4312–4317.
71. Friedlich, A.L., Tanzi, R.E., Rogers, J.T., The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry 12 (2007), 222–223.
72. Friedmann Angeli, J.P., Schneider, M., Proneth, B., Tyurina, Y.Y., Tyurin, V.A., Hammond, V.J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., Basavarajappa, D., Radmark, O., Kobayashi, S., Seibt, T., Beck, H., Neff, F., Esposito, I., Wanke, R., Forster, H., Yefremova, O., Heinrichmeyer, M., Bornkamm, G.W., Geissler, E.K., Thomas, S.B., Stockwell, B.R., O'Donnell, V.B., Kagan, V.E., Schick, J.A., Conrad, M., Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16 (2014), 1180–1191.
73. Frisch, S.M., Francis, H., Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124 (1994), 619–626.
74. Frisch, S.M., Vuori, K., Kelaita, D., Sicks, S., A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA. J. Cell Biol. 135 (1996), 1377–1382.
75. Fuchs, J., Nilsson, C., Kachergus, J., Munz, M., Larsson, E.M., Schule, B., Langston, J.W., Middleton, F.A., Ross, O.A., Hulihan, M., Gasser, T., Farrer, M.J., Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68 (2007), 916–922.
76. Gaal, J.C., Smith, Kevin R., Pearson, Colin K., Cellular euthanasia mediated by a nuclear enzyme: a central role for nuclear ADP-ribosylation in cellular metabolism. Trends Biochem. Sci. 12 (1987), 129–130.
77. Gallant, P., Nigg, E.A., Cyclin B2 undergoes cell cycle-dependent nuclear translocation and, when expressed as a non-destructible mutant, causes mitotic arrest in HeLa cells. J. Cell Biol. 117 (1992), 213–224.
78. Galluzzi, L., Maiuri, M.C., Vitale, I., Zischka, H., Castedo, M., Zitvogel, L., Kroemer, G., Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 14 (2007), 1237–1243.
79. Galluzzi, L., Vitale, I., Abrams, J.M., Alnemri, E.S., Baehrecke, E.H., Blagosklonny, M.V., Dawson, T.M., Dawson, V.L., El-Deiry, W.S., Fulda, S., Gottlieb, E., Green, D.R., Hengartner, M.O., Kepp, O., Knight, R.A., Kumar, S., Lipton, S.A., Lu, X., Madeo, F., Malorni, W., Mehlen, P., Nunez, G., Peter, M.E., Piacentini, M., Rubinsztein, D.C., Shi, Y., Simon, H.U., Vandenabeele, P., White, E., Yuan, J., Zhivotovsky, B., Melino, G., Kroemer, G., Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 19 (2012), 107–120.
80. Gary, D.S., Mattson, M.P., Integrin signaling via the PI3-kinase-Akt pathway increases neuronal resistance to glutamate-induced apoptosis. J. Neurochem. 76 (2001), 1485–1496.
81. Giasson, B.I., Murray, I.V., Trojanowski, J.Q., Lee, V.M., A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276 (2001), 2380–2386.
82. Gibb, W.R., Lees, A.J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51 (1988), 745–752.
83. Goldstein, J.C., Waterhouse, N.J., Juin, P., Evan, G.I., Green, D.R., The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat. Cell Biol. 2 (2000), 156–162.
84. Golstein, P., Kroemer, G., Cell death by necrosis: towards a molecular definition. Trends Biochem. Sci. 32 (2007), 37–43.
85. Golts, N., Snyder, H., Frasier, M., Theisler, C., Choi, P., Wolozin, B., Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277 (2002), 16116–16123.
86. Good, P.F., Olanow, C.W., Perl, D.P., Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593 (1992), 343–346.
87. Graziani, G., Szabo, C., Clinical perspectives of PARP inhibitors. Pharmacol. Res. 52 (2005), 109–118.
88. Gusdon, A.M., Zhu, J., Van Houten, B., Chu, C.T., ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol. Dis. 45 (2012), 962–972.
89. Halliday, G., Brooks, W., Arthur, H., Creasey, H., Broe, G.A., Further evidence for an association between a mutation in the APP gene and Lewy body formation. Neurosci. Lett. 227 (1997), 49–52.
90. Hare, D.J., Lei, P., Ayton, S., Roberts, B.R., Grimm, R., George, J.L., Bishop, D.P., Beavis, A.D., Donovan, S.J., McColl, G., Volitakis, I., An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chem. Sci. 5 (2014), 2160–2169.
91. Hartmann, A., Hunot, S., Michel, P.P., Muriel, M.P., Vyas, S., Faucheux, B.A., Mouatt-Prigent, A., Turmel, H., Srinivasan, A., Ruberg, M., Evan, G.I., Agid, Y., Hirsch, E.C., Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 2875–2880.
92. Hartmann, A., Troadec, J.D., Hunot, S., Kikly, K., Faucheux, B.A., Mouatt-Prigent, A., Ruberg, M., Agid, Y., Hirsch, E.C., Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci. Official J. Soc. Neurosci. 21 (2001), 2247–2255.
93. Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., Masliah, E., Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10 (1999), 717–721.
94. Hassler, R., Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48 (1938), 387–476.
95. He, K.L., Ting, A.T., A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol. Cell. Biol. 22 (2002), 6034–6045.
96. He, Y., Lee, T., Leong, S.K., 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra. Brain Res. 858 (2000), 163–166.
97. Hider, R.C., Kong, X.L., Glutathione: a key component of the cytoplasmic labile iron pool. Biometals Int. J. Role Metal Ions Biol. Biochem. Med. 24 (2011), 1179–1187.
98. Hirsch, E., Graybiel, A.M., Agid, Y.A., Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988), 345–348.
99. Hirsch, E.C., Brandel, J.P., Galle, P., Javoy-Agid, F., Agid, Y., Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56 (1991), 446–451.
100. Hochstrasser, H., Bauer, P., Walter, U., Behnke, S., Spiegel, J., Csoti, I., Zeiler, B., Bornemann, A., Pahnke, J., Becker, G., Riess, O., Berg, D., Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63 (2004), 1912–1917.
101. Hockenbery, D.M., Oltvai, Z.N., Yin, X.M., Milliman, C.L., Korsmeyer, S.J., Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75 (1993), 241–251.
102. Hollerhage, M., Goebel, J.N., de Andrade, A., Hildebrandt, T., Dolga, A., Culmsee, C., Oertel, W.H., Hengerer, B., Hoglinger, G.U., Trifluoperazine rescues human dopaminergic cells from wild-type alpha-synuclein-induced toxicity. Neurobiol. Aging 35 (2014), 1700–1711.
103. Hou, W., Xie, Y., Song, X., Sun, X., Lotze, M.T., Zeh, H.J. 3rd, Kang, R., Tang, D., Autophagy promotes ferroptosis by degradation of ferritin. Autophagy, 0, 2016.
104. Hsu, H., Huang, J., Shu, H.B., Baichwal, V., Goeddel, D.V., TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 (1996), 387–396.
105. Hsu, H., Shu, H.B., Pan, M.G., Goeddel, D.V., TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84 (1996), 299–308.
106. Hsu, H., Xiong, J., Goeddel, D.V., The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81 (1995), 495–504.
107. Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55 (1992), 181–184.
108. Hunot, S., Boissiere, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., Hirsch, E.C., Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72 (1996), 355–363.
109. Hussain, A.R., Al-Rasheed, M., Manogaran, P.S., Al-Hussein, K.A., Platanias, L.C., Al Kuraya, K., Uddin, S., Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis Int. J. Program. Cell Death 11 (2006), 245–254.
110. Ikeuchi, T., Kakita, A., Shiga, A., Kasuga, K., Kaneko, H., Tan, C.F., Idezuka, J., Wakabayashi, K., Onodera, O., Iwatsubo, T., Nishizawa, M., Takahashi, H., Ishikawa, A., Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch. Neurol. 65 (2008), 514–519.
111. Jenner, P., Dexter, D.T., Sian, J., Schapira, A.H., Marsden, C.D., Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group Ann. Neurol., 32, 1992 Suppl:S82–87.
112. Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., Yoshimori, T., LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19 (2000), 5720–5728.
113. Kagan, V.E., Mao, G., Qu, F., Angeli, J.P., Doll, S., Croix, C.S., Dar, H.H., Liu, B., Tyurin, V.A., Ritov, V.B., Kapralov, A.A., Amoscato, A.A., Jiang, J., Anthonymuthu, T., Mohammadyani, D., Yang, Q., Proneth, B., Klein-Seetharaman, J., Watkins, S., Bahar, I., Greenberger, J., Mallampalli, R.K., Stockwell, B.R., Tyurina, Y.Y., Conrad, M., Bayir, H., Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13 (2017), 81–90.
114. Kalivendi, S.V., Cunningham, S., Kotamraju, S., Joseph, J., Hillard, C.J., Kalyanaraman, B., Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. 279 (2004), 15240–15247.
115. Kaur, D., Lee, D., Ragapolan, S., Andersen, J.K., Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. Free Radic. Biol. Med. 46 (2009), 593–598.
116. Kelliher, M.A., Grimm, S., Ishida, Y., Kuo, F., Stanger, B.Z., Leder, P., The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8 (1998), 297–303.
117. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H., Downward, J., Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16 (1997), 2783–2793.
118. Kim, J.H., Lewin, T.M., Coleman, R.A., Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. J. Biol. Chem. 276 (2001), 24667–24673.
119. Kim, K.S., Choi, S.Y., Kwon, H.Y., Won, M.H., Kang, T.C., Kang, J.H., The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro. Biochimie 84 (2002), 625–631.
120. Klionsky, D.J., Emr, S.D., Autophagy as a regulated pathway of cellular degradation. Science 290 (2000), 1717–1721.
121. Ko, H.S., Lee, Y., Shin, J.H., Karuppagounder, S.S., Gadad, B.S., Koleske, A.J., Pletnikova, O., Troncoso, J.C., Dawson, V.L., Dawson, T.M., Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 16691–16696.
122. Kohno, S., Miyajima, H., Takahashi, Y., Inoue, Y., Aceruloplasminemia with a novel mutation associated with parkinsonism. Neurogenetics 2 (2000), 237–238.
123. Kong, S.M., Chan, B.K., Park, J.S., Hill, K.J., Aitken, J.B., Cottle, L., Farghaian, H., Cole, A.R., Lay, P.A., Sue, C.M., Cooper, A.A., Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes alpha-Synuclein externalization via exosomes. Hum. Mol. Genet. 23 (2014), 2816–2833.
124. Koprich, J.B., Reske-Nielsen, C., Mithal, P., Isacson, O., Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflammation, 5, 2008, 8.
125. Kordower, J.H., Olanow, C.W., Dodiya, H.B., Chu, Y., Beach, T.G., Adler, C.H., Halliday, G.M., Bartus, R.T., Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain J. Neurol. 136 (2013), 2419–2431.
126. Kosel, S., Egensperger, R., von Eitzen, U., Mehraein, P., Graeber, M.B., On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol. 93 (1997), 105–108.
127. Krebiehl, G., Ruckerbauer, S., Burbulla, L.F., Kieper, N., Maurer, B., Waak, J., Wolburg, H., Gizatullina, Z., Gellerich, F.N., Woitalla, D., Riess, O., Kahle, P.J., Proikas-Cezanne, T., Kruger, R., Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One, 5, 2010, e9367.
128. Kroemer, G., Galluzzi, L., Brenner, C., Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87 (2007), 99–163.
129. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E.S., Baehrecke, E.H., Blagosklonny, M.V., El-Deiry, W.S., Golstein, P., Green, D.R., Hengartner, M., Knight, R.A., Kumar, S., Lipton, S.A., Malorni, W., Nunez, G., Peter, M.E., Tschopp, J., Yuan, J., Piacentini, M., Zhivotovsky, B., Melino, G., D. Nomenclature Committee on Cell. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 16 (2009), 3–11.
130. Kroemer, G., Petit, P., Zamzami, N., Vayssiere, J.L., Mignotte, B., The biochemistry of programmed cell death. FASEB J. Official Publ. Fed. Am. Soc. Exp. Biol. 9 (1995), 1277–1287.
131. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L., Riess, O., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998), 106–108.
132. Kushnareva, Y., Andreyev, A.Y., Kuwana, T., Newmeyer, D.D., Bax activation initiates the assembly of a multimeric catalyst that facilitates Bax pore formation in mitochondrial outer membranes. PLoS Biol., 10, 2012, e1001394.
133. Kuwana, T., Mackey, M.R., Perkins, G., Ellisman, M.H., Latterich, M., Schneiter, R., Green, D.R., Newmeyer, D.D., Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111 (2002), 331–342.
134. Lee, F.J., Liu, F., Pristupa, Z.B., Niznik, H.B., Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. Official Publ. Fed. Am. Soc. Exp. Biol. 15 (2001), 916–926.
135. Lee, S.S., Kim, Y.M., Junn, E., Lee, G., Park, K.H., Tanaka, M., Ronchetti, R.D., Quezado, M.M., Mouradian, M.M., Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. Neurobiol. Aging 24 (2003), 687–696.
136. Lee, Y., Karuppagounder, S.S., Shin, J.H., Lee, Y.I., Ko, H.S., Swing, D., Jiang, H., Kang, S.U., Lee, B.D., Kang, H.C., Kim, D., Tessarollo, L., Dawson, V.L., Dawson, T.M., Corrigendum: parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat. Neurosci., 18, 2015, 1861.
137. Lei, P., Ayton, S., Appukuttan, A.T., Volitakis, I., Adlard, P.A., Finkelstein, D.I., Bush, A.I., Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol. Dis. 81 (2015), 168–175.
138. Lei, P., Ayton, S., Finkelstein, D.I., Spoerri, L., Ciccotosto, G.D., Wright, D.K., Wong, B.X., Adlard, P.A., Cherny, R.A., Lam, L.Q., Roberts, B.R., Volitakis, I., Egan, G.F., McLean, C.A., Cappai, R., Duce, J.A., Bush, A.I., Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18 (2012), 291–295.
139. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., Pieri, L., Madiona, K., Durr, A., Melki, R., Verny, C., Brice, A., G. French Parkinson's Disease Genetics Study. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73 (2013), 459–471.
140. Leu, J.I., Dumont, P., Hafey, M., Murphy, M.E., George, D.L., Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 6 (2004), 443–450.
141. Li, A.E., Ito, H., Rovira II, Kim, K.S., Takeda, K., Yu, Z.Y., Ferrans, V.J., Finkel, T., A role for reactive oxygen species in endothelial cell anoikis. Circ. Res. 85 (1999), 304–310.
142. Li, H., Zhu, H., Xu, C.J., Yuan, J., Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998), 491–501.
143. Li, L.Y., Luo, X., Wang, X., Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412 (2001), 95–99.
144. Li, Y., Yang, X., Ma, C., Qiao, J., Zhang, C., Necroptosis contributes to the NMDA-induced excitotoxicity in rat's cultured cortical neurons. Neurosci. Lett. 447 (2008), 120–123.
145. Linert, W., Herlinger, E., Jameson, R.F., Kienzl, E., Jellinger, K., Youdim, M.B., Dopamine, 6-hydroxydopamine, iron, and dioxygen–their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316 (1996), 160–168.
146. Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q., Lee, V.M., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 (2012), 949–953.
147. Mandir, A.S., Przedborski, S., Jackson-Lewis, V., Wang, Z.Q., Simbulan-Rosenthal, C.M., Smulson, M.E., Hoffman, B.E., Guastella, D.B., Dawson, V.L., Dawson, T.M., Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 5774–5779.
148. Marsden, C.D., Parkes, J.D., Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977), 345–349.
149. Marti, M.J., Saura, J., Burke, R.E., Jackson-Lewis, V., Jimenez, A., Bonastre, M., Tolosa, E., Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat. Brain Res. 958 (2002), 185–191.
150. Martin, L.J., Pan, Y., Price, A.C., Sterling, W., Copeland, N.G., Jenkins, N.A., Price, D.L., Lee, M.K., Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. Official J. Soc. Neurosci. 26 (2006), 41–50.
151. Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A.C., Mazzulli, J., Mosharov, E.V., Hodara, R., Fredenburg, R., Wu, D.C., Follenzi, A., Dauer, W., Przedborski, S., Ischiropoulos, H., Lansbury, P.T., Sulzer, D., Cuervo, A.M., Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Investig. 118 (2008), 777–788.
152. Martinon, F., Burns, K., Tschopp, J., The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10 (2002), 417–426.
153. Martinou, J.C., Green, D.R., Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell Biol. 2 (2001), 63–67.
154. Mastroberardino, P.G., Hoffman, E.K., Horowitz, M.P., Betarbet, R., Taylor, G., Cheng, D., Na, H.M., Gutekunst, C.A., Gearing, M., Trojanowski, J.Q., Anderson, M., Chu, C.T., Peng, J., Greenamyre, J.T., A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 34 (2009), 417–431.
155. Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D.M., Hasegawa, M., Prion-like spreading of pathological alpha-synuclein in brain. Brain J. Neurol. 136 (2013), 1128–1138.
156. Miyajima, H., Takahashi, Y., Kono, S., Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals Int. J. Role Metal Ions Biol. Biochem. Med. 16 (2003), 205–213.
157. Miyawaki, E., Lyons, K., Pahwa, R., Troster, A.I., Hubble, J., Smith, D., Busenbark, K., McGuire, D., Michalek, D., Koller, W.C., Motor complications of chronic levodopa therapy in Parkinson's disease. Clin. Neuropharmacol. 20 (1997), 523–530.
158. Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M.D., Klionsky, D.J., Ohsumi, M., Ohsumi, Y., A protein conjugation system essential for autophagy. Nature 395 (1998), 395–398.
159. Mochizuki, H., Imai, H., Endo, K., Yokomizo, K., Murata, Y., Hattori, N., Mizuno, Y., Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168 (1994), 251–253.
160. Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., Nagatsu, T., Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 (1994), 208–210.
161. Monti, D.A., Zabrecky, G., Kremens, D., Liang, T.W., Wintering, N.A., Cai, J., Wei, X., Bazzan, A.J., Zhong, L., Bowen, B., Intenzo, C.M., Iacovitti, L., Newberg, A.B., N-acetyl cysteine may support dopamine neurons in Parkinson's disease: preliminary clinical and cell line data. PLos One, 11, 2016, e0157602.
162. Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T., Tsujimoto, Y., Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005), 652–658.
163. Nakano, I., Hirano, A., Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann. Neurol. 15 (1984), 415–418.
164. Nielsen, J.E., Jensen, L.N., Krabbe, K., Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J. Neurol. Neurosurg. Psychiatry 59 (1995), 318–321.
165. Nomura, M., Ueno, A., Saga, K., Fukuzawa, M., Kaneda, Y., Accumulation of cytosolic calcium induces necroptotic cell death in human neuroblastoma. Cancer Res. 74 (2014), 1056–1066.
166. Obi, T., Nishioka, K., Ross, O.A., Terada, T., Yamazaki, K., Sugiura, A., Takanashi, M., Mizoguchi, K., Mori, H., Mizuno, Y., Hattori, N., Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 70 (2008), 238–241.
167. Oltvai, Z.N., Milliman, C.L., Korsmeyer, S.J., Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993), 609–619.
168. Osaki, S., Johnson, D.A., Frieden, E., The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J. Biol. Chem. 241 (1966), 2746–2751.
169. Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M., Wolozin, B., The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. Official J. Soc. Neurosci. 20 (2000), 6048–6054.
170. Outeiro, T.F., Grammatopoulos, T.N., Altmann, S., Amore, A., Standaert, D.G., Hyman, B.T., Kazantsev, A.G., Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. Biochem. Biophys. Res. Commun. 357 (2007), 596–602.
171. Paik, S.R., Shin, H.J., Lee, J.H., Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch. Biochem. Biophys. 378 (2000), 269–277.
172. Pankratz, N., Wilk, J.B., Latourelle, J.C., DeStefano, A.L., Halter, C., Pugh, E.W., Doheny, K.F., Gusella, J.F., Nichols, W.C., Foroud, T., Myers, R.H., Psg, P., C. GenePd Investigators, and L. Molecular Genetic. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124 (2009), 593–605.
173. Parihar, M.S., Parihar, A., Fujita, M., Hashimoto, M., Ghafourifar, P., Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. CMLS 65 (2008), 1272–1284.
174. Park, S.W., Kim, S.H., Park, K.H., Kim, S.D., Kim, J.Y., Baek, S.Y., Chung, B.S., Kang, C.D., Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci. Lett. 363 (2004), 243–246.
175. Peng, Y., Wang, C., Xu, H.H., Liu, Y.N., Zhou, F., Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J. Inorg. Biochem. 104 (2010), 365–370.
176. Perry, T.L., Yong, V.W., Clavier, R.M., Jones, K., Wright, J.M., Foulks, J.G., Wall, R.A., Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60 (1985), 109–114.
177. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., Nussbaum, R.L., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
178. Proukakis, C., Dudzik, C.G., Brier, T., Mackay, D.S., Cooper, J.M., Millhauser, G.L., Houlden, H., Schapira, A.H., A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80 (2013), 1062–1064.
179. Qiao, L., Hamamichi, S., Caldwell, K.A., Caldwell, G.A., Yacoubian, T.A., Wilson, S., Xie, Z.L., Speake, L.D., Parks, R., Crabtree, D., Liang, Q., Crimmins, S., Schneider, L., Uchiyama, Y., Iwatsubo, T., Zhou, Y., Peng, L., Lu, Y., Standaert, D.G., Walls, K.C., Shacka, J.J., Roth, K.A., Zhang, J., Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain, 1, 2008, 17.
180. Raisova, M., Hossini, A.M., Eberle, J., Riebeling, C., Wieder, T., Sturm, I., Daniel, P.T., Orfanos, C.E., Geilen, C.C., The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J. Investig. Dermatol. 117 (2001), 333–340.
181. Ramirez, A., Heimbach, A., Grundemann, J., Stiller, B., Hampshire, D., Cid, L.P., Goebel, I., Mubaidin, A.F., Wriekat, A.L., Roeper, J., Al-Din, A., Hillmer, A.M., Karsak, M., Liss, B., Woods, C.G., Behrens, M.I., Kubisch, C., Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38 (2006), 1184–1191.
182. Rhodes, S.L., Buchanan, D.D., Ahmed, I., Taylor, K.D., Loriot, M.A., Sinsheimer, J.S., Bronstein, J.M., Elbaz, A., Mellick, G.D., Rotter, J.I., Ritz, B., Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin. Neurobiol. Dis. 62 (2014), 172–178.
183. Rinne, J.O., Rummukainen, J., Paljarvi, L., Rinne, U.K., Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann. Neurol. 26 (1989), 47–50.
184. Rinne, J.O., Rummukainen, J., Paljarvi, L., Sako, E., Molsa, P., Rinne, U.K., Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia. Prog. Clin. Biol. Res. 317 (1989), 325–332.
185. Rosenberg, C.K., Pericak-Vance, M.A., Saunders, A.M., Gilbert, J.R., Gaskell, P.C., Hulette, C.M., Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation. Acta Neuropathol. 100 (2000), 145–152.
186. Sacino, A.N., Brooks, M., Thomas, M.A., McKinney, A.B., Lee, S., Regenhardt, R.W., McGarvey, N.H., Ayers, J.I., Notterpek, L., Borchelt, D.R., Golde, T.E., Giasson, B.I., Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 10732–10737.
187. Saha, A.R., Ninkina, N.N., Hanger, D.P., Anderton, B.H., Davies, A.M., Buchman, V.L., Induction of neuronal death by alpha-synuclein. Eur. J. Neurosci. 12 (2000), 3073–3077.
188. Sarkar, S., Floto, R.A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M., Cook, L.J., Rubinsztein, D.C., Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170 (2005), 1101–1111.
189. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., Tomiyama, H., Nakashima, K., Hasegawa, K., Obata, F., Yoshikawa, T., Kawakami, H., Sakoda, S., Yamamoto, M., Hattori, N., Murata, M., Nakamura, Y., Toda, T., Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41 (2009), 1303–1307.
190. Schober, A., Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318 (2004), 215–224.
191. Schulte, E.C., Fukumori, A., Mollenhauer, B., Hor, H., Arzberger, T., Perneczky, R., Kurz, A., Diehl-Schmid, J., Hull, M., Lichtner, P., Eckstein, G., Zimprich, A., Haubenberger, D., Pirker, W., Brucke, T., Bereznai, B., Molnar, M.J., Lorenzo-Betancor, O., Pastor, P., Peters, A., Gieger, C., Estivill, X., Meitinger, T., Kretzschmar, H.A., Trenkwalder, C., Haass, C., Winkelmann, J., Rare variants in beta-Amyloid precursor protein (APP) and Parkinson's disease. Eur. J. Hum. Genet. EJHG, 2015.
192. Shimamura, H., Terada, Y., Okado, T., Tanaka, H., Inoshita, S., Sasaki, S., The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-kappa B and Bad. J. Am. Soc. Nephrol. JASN 14 (2003), 1427–1434.
193. Shirvan, A., Ziv, I., Barzilai, A., Djaldeti, R., Zilkh-Falb, R., Michlin, T., Melamed, E., Induction of mitosis-related genes during dopamine-triggered apoptosis in sympathetic neurons. J. Neural Transm. Suppl. 50 (1997), 67–78.
194. Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., Marsden, C.D., Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36 (1994), 348–355.
195. Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G., Kruger, R., Federoff, M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M.A., Illig, T., Gieger, C., Houlden, H., Steffens, M., Okun, M.S., Racette, B.A., Cookson, M.R., Foote, K.D., Fernandez, H.H., Traynor, B.J., Schreiber, S., Arepalli, S., Zonozi, R., Gwinn, K., van der Brug, M., Lopez, G., Chanock, S.J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X., Wood, N.W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J.A., Singleton, A.B., Gasser, T., Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41 (2009), 1308–1312.
196. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., Gwinn-Hardy, K., alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 2003, 841.
197. Skouta, R., Dixon, S.J., Wang, J., Dunn, D.E., Orman, M., Shimada, K., Rosenberg, P.A., Lo, D.C., Weinberg, J.M., Linkermann, A., Stockwell, B.R., Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136 (2014), 4551–4556.
198. Slee, E.A., Adrain, C., Martin, S.J., Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 276 (2001), 7320–7326.
199. Smith, W.W., Jiang, H., Pei, Z., Tanaka, Y., Morita, H., Sawa, A., Dawson, V.L., Dawson, T.M., Ross, C.A., Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum. Mol. Genet. 14 (2005), 3801–3811.
200. Sofic, E., Lange, K.W., Jellinger, K., Riederer, P., Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142 (1992), 128–130.
201. Sofic, E., Paulus, W., Jellinger, K., Riederer, P., Youdim, M.B., Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56 (1991), 978–982.
202. Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G.P., Hebenstreit, G., Youdim, M.B., Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74 (1988), 199–205.
203. Song, J.X., Lu, J.H., Liu, L.F., Chen, L.L., Durairajan, S.S., Yue, Z., Zhang, H.Q., Li, M., HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy 10 (2014), 144–154.
204. Sousa, S.C., Maciel, E.N., Vercesi, A.E., Castilho, R.F., Ca2+-induced oxidative stress in brain mitochondria treated with the respiratory chain inhibitor rotenone. FEBS Lett. 543 (2003), 179–183.
205. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
206. Sriram, K., Matheson, J.M., Benkovic, S.A., Miller, D.B., Luster, M.I., O'Callaghan, J.P., Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. Official Publ. Fed. Am. Soc. Exp. Biol. 16 (2002), 1474–1476.
207. Sriram, K., Pai, K.S., Boyd, M.R., Ravindranath, V., Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 749 (1997), 44–52.
208. Su, X., Federoff, H.J., Maguire-Zeiss, K.A., Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox. Res. 16 (2009), 238–254.
209. Susin, S.A., Lorenzo, H.K., Zamzami, N., Marzo, I., Snow, B.E., Brothers, G.M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D.R., Aebersold, R., Siderovski, D.P., Penninger, J.M., Kroemer, G., Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999), 441–446.
210. Tamura, T., Ishihara, M., Lamphier, M.S., Tanaka, N., Oishi, I., Aizawa, S., Matsuyama, T., Mak, T.W., Taki, S., Taniguchi, T., An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 376 (1995), 596–599.
211. Tan, M.S., Tan, L., Jiang, T., Zhu, X.C., Wang, H.F., Jia, C.D., Yu, J.T., Amyloid-beta induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer's disease. Cell Death Dis., 5, 2014, e1382.
212. Tanaka, Y., Engelender, S., Igarashi, S., Rao, R.K., Wanner, T., Tanzi, R.E., Sawa, A., Dawson, V.L., Dawson, T.M., Ross, C.A., Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10 (2001), 919–926.
213. Tarze, A., Deniaud, A., Le Bras, M., Maillier, E., Molle, D., Larochette, N., Zamzami, N., Jan, G., Kroemer, G., Brenner, C., GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene 26 (2007), 2606–2620.
214. Tatton, N.A., Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166 (2000), 29–43.
215. Thomas, B., Banerjee, R., Starkova, N.N., Zhang, S.F., Calingasan, N.Y., Yang, L., Wille, E., Lorenzo, B.J., Ho, D.J., Beal, M.F., Starkov, A., Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease. Antioxid. Redox Signal. 16 (2012), 855–868.
216. Torii, S., Shintoku, R., Kubota, C., Yaegashi, M., Torii, R., Sasaki, M., Suzuki, T., Mori, M., Yoshimoto, Y., Takeuchi, T., Yamada, K., An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem. J. 473 (2016), 769–777.
217. Ursini, F., Bindoli, A., The role of selenium peroxidases in the protection against oxidative damage of membranes. Chem. Phys. Lipids 44 (1987), 255–276.
218. Ursini, F., Maiorino, M., Valente, M., Ferri, L., Gregolin, C., Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochim. Biophys. Acta 710 (1982), 197–211.
219. Uversky, V.N., Li, J., Fink, A.L., Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276 (2001), 44284–44296.
220. Van Antwerp, D.J., Martin, S.J., Kafri, T., Green, D.R., Verma, I.M., Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274 (1996), 787–789.
221. Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S.J., Przedborski, S., Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 2837–2842.
222. Viswanath, V., Wu, Y., Boonplueang, R., Chen, S., Stevenson, F.F., Yantiri, F., Yang, L., Beal, M.F., Andersen, J.K., Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. Official J. Soc. Neurosci. 21 (2001), 9519–9528.
223. Wang, L., Du, F., Wang, X., TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133 (2008), 693–703.
224. Wang, Y., Kim, N.S., Haince, J.F., Kang, H.C., David, K.K., Andrabi, S.A., Poirier, G.G., Dawson, V.L., Dawson, T.M., Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci. Signal., 4, 2011, ra20.
225. Wei, M.C., Zong, W.X., Cheng, E.H., Lindsten, T., Panoutsakopoulou, V., Ross, A.J., Roth, K.A., MacGregor, G.R., Thompson, C.B., Korsmeyer, S.J., Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001), 727–730.
226. Williams, A., Sarkar, S., Cuddon, P., Ttofi, E.K., Saiki, S., Siddiqi, F.H., Jahreiss, L., Fleming, A., Pask, D., Goldsmith, P., O'Kane, C.J., Floto, R.A., Rubinsztein, D.C., Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 4 (2008), 295–305.
227. Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., Pham, E., Masliah, E., Gage, F.H., Riek, R., In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 4194–4199.
228. Winslow, A.R., Chen, C.W., Corrochano, S., Acevedo-Arozena, A., Gordon, D.E., Peden, A.A., Lichtenberg, M., Menzies, F.M., Ravikumar, B., Imarisio, S., Brown, S., O'Kane, C.J., Rubinsztein, D.C., alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 190 (2010), 1023–1037.
229. Wu, J.R., Wang, J., Zhou, S.K., Yang, L., Yin, J.L., Cao, J.P., Cheng, Y.B., Necrostatin-1 protection of dopaminergic neurons. Neural Regen. Res. 10 (2015), 1120–1124.
230. Xilouri, M., Vogiatzi, T., Vekrellis, K., Park, D., Stefanis, L., Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One, 4, 2009, e5515.
231. Yang, L., Sugama, S., Mischak, R.P., Kiaei, M., Bizat, N., Brouillet, E., Joh, T.H., Beal, M.F., A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol. Dis. 17 (2004), 250–259.
232. Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., Brown, L.M., Girotti, A.W., Cornish, V.W., Schreiber, S.L., Stockwell, B.R., Regulation of ferroptotic cancer cell death by GPX4. Cell 156 (2014), 317–331.
233. Yang, W.S., Stockwell, B.R., Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15 (2008), 234–245.
234. Yin, C., Knudson, C.M., Korsmeyer, S.J., Van Dyke, T., Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385 (1997), 637–640.
235. Yu, S.W., Andrabi, S.A., Wang, H., Kim, N.S., Poirier, G.G., Dawson, T.M., Dawson, V.L., Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 18314–18319.
236. Yu, W.B., Jiang, T., Lan, D.M., Lu, J.H., Yue, Z.Y., Wang, J., Zhou, P., Trehalose inhibits fibrillation of A53T mutant alpha-synuclein and disaggregates existing fibrils. Arch. Biochem. Biophys. 523 (2012), 144–150.
237. Zarow, C., Lyness, S.A., Mortimer, J.A., Chui, H.C., Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60 (2003), 337–341.
238. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, D.G., de Yebenes, J.G., The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004), 164–173.
239. Zeron, M.M., Fernandes, H.B., Krebs, C., Shehadeh, J., Wellington, C.L., Leavitt, B.R., Baimbridge, K.G., Hayden, M.R., Raymond, L.A., Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 25 (2004), 469–479.
240. Zhang, W., Wang, T., Pei, Z., Miller, D.S., Wu, X., Block, M.L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.S., Zhang, J., Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. Official Publ. Fed. Am. Soc. Exp. Biol. 19 (2005), 533–542.
241. Zou, H., Li, Y., Liu, X., Wang, X., An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274 (1999), 11549–11556.